37 related articles for article (PubMed ID: 6196891)
1. Efficacy and toxicity of mustargen, vincristine, procarbazine and prednisone (MOPP) for the treatment of relapsed or resistant lymphoma in cats.
MaloneyHuss MA; Mauldin GE; Brown DC; Veluvolu SM; Krick EL
J Feline Med Surg; 2020 Apr; 22(4):299-304. PubMed ID: 30994392
[TBL] [Abstract][Full Text] [Related]
2. Hodgkin's lymphoma rectosigmoid in a patient with ulcerative colitis on long-term azathioprine therapy.
Khuroo MS
BMJ Case Rep; 2014 May; 2014():. PubMed ID: 24849639
[TBL] [Abstract][Full Text] [Related]
3. Monoamine oxidase A is highly expressed in classical Hodgkin lymphoma.
Li PC; Siddiqi IN; Mottok A; Loo EY; Wu CH; Cozen W; Steidl C; Shih JC
J Pathol; 2017 Oct; 243(2):220-229. PubMed ID: 28722111
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
Piga A; Ambrosetti A; Todeschini G; Cetto G; Perona G; Cellerino R
Cancer Treat Rep; 1984; 68(7-8):947-51. PubMed ID: 6204754
[TBL] [Abstract][Full Text] [Related]
5. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
[TBL] [Abstract][Full Text] [Related]
6. Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD).
Santoro A; Bonadonna G
Cancer Chemother Pharmacol; 1979; 2(2):101-5. PubMed ID: 93984
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) after failure of MOPP therapy.
Krikorian JG; Portlock CS; Rosenberg SA
Cancer; 1978 Jun; 41(6):2107-11. PubMed ID: 77716
[TBL] [Abstract][Full Text] [Related]
8. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP.
Santoro A; Viviani S; Villarreal CJ; Bonfante V; Delfino A; Valagussa P; Bonadonna G
Cancer Treat Rep; 1986 Mar; 70(3):343-8. PubMed ID: 2420444
[TBL] [Abstract][Full Text] [Related]
9. MOPP treatment of resistant Hodgkin's disease following ABVD failure.
Cimino G; Anselmo AP; Marzullo A; Maurizi Enrici R; Mauro F; Papa G; Mandelli F
Tumori; 1983 Oct; 69(5):469-72. PubMed ID: 6196891
[TBL] [Abstract][Full Text] [Related]
10. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
Canellos GP
Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
[TBL] [Abstract][Full Text] [Related]
11. Advanced Hodgkin's disease: ABVD is better, yet is not good enough!
Diehl V
J Clin Oncol; 2003 Feb; 21(4):583-5. PubMed ID: 12586791
[No Abstract] [Full Text] [Related]
12. Chemotherapy strategies to improve the control of Hodgkin's disease: the Richard and Hinda Rosenthal Foundation Award Lecture.
Bonadonna G
Cancer Res; 1982 Nov; 42(11):4309-20. PubMed ID: 6181867
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
